Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)
04 Maio 2023 - 5:33PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
25
NOTIFICATION
OF REMOVAL FROM LISTING AND/OR
REGISTRATION
UNDER SECTION 12(b) OF THE
SECURITIES
EXCHANGE ACT OF 1934.
Commission
File No. 001-35817
Issuer:
Vyant Bio, Inc.
Exchange:
Nasdaq Capital Market
(Exact
name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
2
Executive Campus
2370
State Route 70, Suite 310
Cherry
Hill, NJ 08002
(201)
479-1357
(Address,
including zip code, and telephone number, including area code, of Issuer’s principal executive offices)
Common
stock, par value $0.0001 per share
(Description
of class of securities)
Please
place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
☐ |
17
CFR 240.12d2-2(a)(1) |
☐ |
17
CFR 240.12d2-2(a)(2) |
☐ |
17
CFR 240.12d2-2(a)(3) |
☐ |
17
CFR 240.12d2-2(a)(4) |
☐ |
Pursuant
to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw
registration on the Exchange.1 |
☒ |
Pursuant
to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing
the voluntary withdrawal of the class of securities from listing and registration on the Exchange. |
1 |
Form
25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions. |
Pursuant
to the requirements of the Securities Exchange Act of 1934, Vyant Bio, Inc. (Name of Issuer or Exchange) certifies that it has reasonable
grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its
behalf by the undersigned duly authorized person.
5/4/2023 |
By |
/s/
Andrew D. C. LaFrence |
|
President,
Chief Executive Officer and Chief Financial Officer |
Date |
|
Name |
|
Title |
Cancer Genetics (NASDAQ:CGIX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Cancer Genetics (NASDAQ:CGIX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
Notícias em tempo-real sobre Cancer Genetics Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Vyant Bio, Inc.